Kimball Electronics/$KE

1D1W1MYTD1Y5YMAX

About Kimball Electronics

Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
Ticker
$KE
Sector
Digital Hardware
Primary listing
NASDAQ
Employees
5,600

KE Metrics

BasicAdvanced
$639M
23.59
$1.13
1.21
-

What the Analysts think about KE

Analyst ratings (Buy, Hold, Sell) for Kimball Electronics stock.
Analyst projections of the future price of Kimball Electronics stock.

Bulls say / Bears say

Management projects fiscal 2027 sales of $1.535–$1.560 billion, representing 7%–9% growth, including 3%–5% organic growth. Medical sales are expected to increase at a high-single-digit to low-double-digit rate. (SEC)
The Helvoet acquisition expands Kimball’s medical CDMO capabilities into microfluidics, diagnostics, drug delivery, precision molding, and complex tooling. Management expects approximately $60 million of Helvoet sales in fiscal 2027 and medical to exceed one-third of company revenue, improving business mix. (Kimball Electronics)
Kimball exited fiscal 2026 with $42.4 million of Q4 operating cash flow, its tenth consecutive quarter of positive operating cash generation, $116.6 million of debt, and $322.4 million of borrowing capacity. The stronger balance sheet supports acquisitions, facility investment, and continued share repurchases. (SEC)
Automotive revenue fell 7% in fiscal 2026 and industrial revenue declined 5%, while Q4 automotive and industrial sales were down 3% and 5%, respectively. Continued weakness in these two verticals could offset medical-led growth. (SEC)
The $103 million Helvoet acquisition was funded with cash and existing credit lines, adding execution and balance-sheet risk as Kimball integrates operations across Europe and India. The company also plans $50–$60 million of fiscal 2027 capital expenditures. (SEC)
Fiscal 2027 adjusted operating-margin guidance of 4.4%–4.7% remains modest, and below the 4.9% adjusted margin reported for Q4 fiscal 2026. This leaves limited room for input-cost, tariff, foreign-exchange, or integration pressures before earnings are affected. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.

KE Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

KE Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing KE

Funds
Fund name
Fund size
$KE weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.